Replacement therapy in adults, children and adolescents (0-18 years) in:
- Primary immunodeficiency syndromes with impaired antibody production.
- Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum IgG level of < 4 g/l.
*PSAF = failure to mount at least a 2-fold rise in IgG antibody titre to pneumococcal polysaccharide and polypeptide antigen vaccines.
Immunomodulatory therapy in adults, children and adolescents (0-18 years):
- Hizentra is indicated for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy after stabilization with IVIg.
Hizentra is available in the following presentations:
- 1g in 5ml vial
- 2g in 10ml vial
- 4g in 20ml vial
For details on Hizentra at Home, our homecare services programme please click here.
Please visit our Privigen page for information on our Solution for Infusion, Human Normal Immunoglobulin.
Method of Sale: POM
License Number: EU/1/11/687/001, EU/1/11/687/004 & EU/1/11/687/010
MAH Holder: CSL Behring GmbH
Hizentra is distributed in Ireland by Fannin Ltd. in partnership with CSL Behring. (This link will take you to a non-Fannin Ltd. website. Fannin Ltd. does not recommend, endorse or accept liability for sites controlled by third-parties.)
Date of Preparation: May 2022